DDInter1425 DDInter1376
A potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Pentostatin {u} (Compound) resembles {v} (Compound) Trifluridine
Pentostatin {u} (Compound) resembles {v} (Compound) Azacitidine
Pentostatin {u} (Compound) treats {v} (Disease) hematologic cancer
Pentostatin {u} (Compound) binds {v} (Gene) ADA
Pentostatin {u} (Compound) is included by {v} (Pharmacologic Class) Nucleic Acid Synthesis Inhibitors
Pentostatin {u} (Compound) causes {v} (Side Effect) Foetor hepaticus
Pentostatin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enoxacin
Pentostatin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ofloxacin
Pentostatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aldesleukin
Pentostatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hydroxyurea
Pentostatin (Compound) resembles Trifluridine (Compound)
Pentostatin (Compound) resembles Azacitidine (Compound)
Pentostatin (Compound) treats hematologic cancer (Disease)
Pentostatin (Compound) binds ADA (Gene)
Pentostatin (Compound) is included by Nucleic Acid Synthesis Inhibitors (Pharmacologic Class)
Pentostatin (Compound) causes Foetor hepaticus (Side Effect)
Pentostatin may cause a minor interaction that can limit clinical effects when taken with Enoxacin
Pentostatin may cause a minor interaction that can limit clinical effects when taken with Ofloxacin
Pentostatin may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin
Pentostatin may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyurea